Similar Papers

Paper Title
Journal
Date
Author
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
Hanaa M El-Karaksy ... Doaa Saleh
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research | VOL. 36
Hanaa M El-Karaksy, et. al.Hanaa M El-Karaksy ... Doaa Saleh
25 Sep 2015
Effectiveness of Ombitasvir with Paritaprevir/Ritonavir plus Ribavirin on the Treatment of Naïve Patients with Chronic Hepatitis C Virus Genotype 4
Mohammed Abdel-Gabbar ... Mohammed Alkot
Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) | VOL. 31
Mohammed Abdel-Gabbar, et. al.Mohammed Abdel-Gabbar ... Mohammed Alkot
12 Jun 2022
HOMOZYGOSITY FOR HLA-C2 ALLELES IS NEGATIVELY ASSOCIATED WITH TREATMENT RESPONSE WITH PEGLYATED INTERFERON-γ AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED INDIVIDUALS
M Collison ... R Macnicholas
Gut | VOL. 62
M Collison, et. al.M Collison ... R Macnicholas
08 Jun 2013
Hemoglobin decline above 2g/dl during Peginterferon alfa-2b (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infection without erythropoietin use
G Teuber ... T Dahhan
Zeitschrift für Gastroenterologie | VOL. 51
G Teuber, et. al.G Teuber ... T Dahhan
11 Jan 2013
View more papers

More From: Zeitschrift für Gastroenterologie

Paper Title
Journal
Date
Author
Kolorektales Karzinom: Lenvatinib/Pembrolizumab nicht überlegen
-
Zeitschrift für Gastroenterologie | VOL. -
--
01 Feb 2025
Die DGVS – Neue Mitglieder der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten
-
Zeitschrift für Gastroenterologie | VOL. -
--
01 Feb 2025
Fallvorstellung – LINX-System im MRT
-
Zeitschrift für Gastroenterologie | VOL. -
--
01 Feb 2025
In Erinnerung an Dr. med. Adolf Guttentag (1868–1942)
-
Zeitschrift für Gastroenterologie | VOL. -
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.